EGFR and neoplasm: The arachidonic acid metabolic chain may be inhibited by EGFR-TKIs or PD-1/PD-L1 inhibitors, making it unable to produce pro-inflammatory and pro-tumor substances (such as eicosanoids) through key enzymes in the arachidonic acid metabolic network, thus causing a raise of the arachidonic acid (Koundouros et al., 2020).